The U.S. Food and Drug Administration authorized the emergency use of Pfizer Inc.’s Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for the treatment of mild-to-moderate Covid-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg [88 lbs]) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death.